## Telix Surges as FDA Accepts Review of Brain Cancer Imaging Agent TLX101-CDx
Telix Pharmaceuticals saw its stock rise after the U.S. Food and Drug Administration (FDA) formally accepted its Biologics License Application (BLA) for TLX101-CDx, a novel imaging agent designed to detect brain cancer. This regulatory milestone triggers a standard 10-month review period, putting the company on a clear path toward a potential U.S. market approval for a critical diagnostic tool. The agent, a radiohybrid PSMA-targeting probe, is intended for use with positron emission tomography (PET) to visualize recurrent glioblastoma, an aggressive form of brain cancer with limited current diagnostic options.

The FDA's acceptance for review validates the clinical data package Telix submitted, which includes results from the pivotal Phase III ZIRCON study. This study demonstrated the agent's high sensitivity and specificity in identifying prostate-specific membrane antigen (PSMA) expression in glioblastoma patients, a key biomarker. The move represents a significant step in Telix's strategy to expand its oncology portfolio beyond its already-approved prostate cancer imaging product, Illuccix, into new and challenging cancer types.

Successful approval of TLX101-CDx would address a major unmet medical need in neuro-oncology, potentially improving treatment planning and monitoring for patients with recurrent glioblastoma. For Telix, it represents a key commercial and pipeline diversification opportunity in the large U.S. healthcare market. The company now faces the scrutiny of the FDA's review process, with a Prescription Drug User Fee Act (PDUFA) action date expected in the first quarter of 2025, setting the stage for a definitive regulatory decision.
---
- **Source**: Seeking Alpha
- **Sector**: The Lab
- **Tags**: FDA, Biologics License Application, Brain Cancer, Glioblastoma, Medical Imaging
- **Credibility**: unverified
- **Published**: 2026-04-10 12:22:28
- **ID**: 58792
- **URL**: https://whisperx.ai/en/intel/58792